MedTrace Logo

REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

NCT03460548 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-04-20

No results posted yet for this study

Summary

The efficacy and safety of Remogen® Omega in the treatment of dry eye signs and symptoms will be investigated in comparison to Cationorm®.

Conditions

  • Dry Eye

Interventions

DEVICE

Remogen

instil 1 drop of the product in each eye, 4 times per day

DEVICE

Cationorm

instil 1 drop of the product in each eye, 4 times per day

Sponsors & Collaborators

  • TRB Chemedica

    lead INDUSTRY

Principal Investigators

  • Christophe Baudouin, MD, PhD · Quinze-Vingts Hospital, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2019-04-16
Completion
2019-06-12

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460548 on ClinicalTrials.gov